Cytokinetics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Cytokinetics and other ETFs, options, and stocks.

About CYTK

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. 

CEO
Robert I. Blum
CEORobert I. Blum
Employees
498
Employees498
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
1997
Founded1997
Employees
498
Employees498

CYTK Key Statistics

Market cap
7.68B
Market cap7.68B
Price-Earnings ratio
-9.86
Price-Earnings ratio-9.86
Dividend yield
Dividend yield
Average volume
1.85M
Average volume1.85M
High today
$63.70
High today$63.70
Low today
$62.10
Low today$62.10
Open price
$62.96
Open price$62.96
Volume
605.19K
Volume605.19K
52 Week high
$69.33
52 Week high$69.33
52 Week low
$29.31
52 Week low$29.31

Stock Snapshot

With a market cap of 7.68B, Cytokinetics(CYTK) trades at $62.85. The stock has a price-to-earnings ratio of -9.86.

On 2025-12-19, Cytokinetics(CYTK) stock moved within a range of $62.10 to $63.70. With shares now at $62.85, the stock is trading +1.2% above its intraday low and -1.3% below the session's peak.

Trading volume for Cytokinetics(CYTK) stock has reached 605.19K, versus its average volume of 1.85M.

The stock's 52-week range extends from a low of $29.31 to a high of $69.33.

The stock's 52-week range extends from a low of $29.31 to a high of $69.33.

CYTK News

Nasdaq 1h
This Cytokinetics Director Sold 5,000 Shares in November. Is It Time to Dump the Biopharmaceutical Stock?

Key Points Cytokinetics is a late-stage biopharmaceutical company targeting muscle function. Its stock has gained almost 30% this year, besting the S&P 500....

This Cytokinetics Director Sold 5,000 Shares in November. Is It Time to Dump the Biopharmaceutical Stock?
Investor's Business Daily 5h
Why Cytokinetics CEO Is Optimistic As FDA Deadline On Aficamten Looms

Technology Why Cytokinetics CEO Is Optimistic As FDA Deadline On Aficamten Looms Licensing Cytokinetics (CYTK) is on the cusp of its first Food and Drug Adminis...

Why Cytokinetics CEO Is Optimistic As FDA Deadline On Aficamten Looms
TipRanks 1d
Cytokinetics upgraded to Buy at Goldman on odds of ACACIA succeeding

As previously reported, Goldman Sachs upgraded Cytokinetics (CYTK) to Buy from Neutral with a price target of $95, up from $55. The firm views shares as poised...

Analyst ratings

81%

of 21 ratings
Buy
81%
Hold
19%
Sell
0%

More CYTK News

TipRanks 1d
Cytokinetics upgraded to Buy from Neutral at Goldman Sachs

Goldman Sachs upgraded Cytokinetics (CYTK) to Buy from Neutral with a $95 price target Published first on TheFly – the ultimate source for real-time, market-mo...

TipRanks 2d
Cytokinetics announces MYQORZO approved by China NMPA

Cytokinetics (CYTK), Incorporated announced that MYQORZO has been approved by the China National Medical Products Administration, NMPA, for the treatment of adu...

TipRanks 3d
Top Executive Sells Thousands in Cytokinetics Stock!

New insider activity at Cytokinetics ( (CYTK) ) has taken place on December 16, 2025. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fun...

People also own

Based on the portfolios of people who own CYTK. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.